急性髓性白血病

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.

• 全文
• 摘要

Marsh JC, Ball SE, Cavanagh J, et al; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147:43-70.

• 全文
• 摘要

Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant. 2006;37:249-261.

• 全文
• 摘要

National Cancer Comprehensive Network. NCCN guidelines: acute myeloid leukemia. Version 3. 2017. http://www.nccn.org (last accessed 21 June 2017).

• 全文

Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31:3360-3368.

• 摘要

1.  Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.

• 全文
• 摘要

2.  Appelbaum FR. Acute myeloid leukemia in adults. In: Abeloff MD, Armitage JO, Niederhuber JE, et al, eds. Clinical oncology. 3rd ed. Philadelphia, PA: Elsevier; 2004:2825-2848.

3.  Cancer Research UK. Acute myeloid leukaemia (AML) incidence statistics. June 2014. http://www.cancerresearchuk.org/ (last accessed 21 June 2017).

• 全文

4.  American Cancer Society. Cancer facts & figures 2017. https://www.cancer.org/ (last accessed 12 September 2017).

• 全文

5.  National Cancer Institute: Surveillance, Epidemiology, and End Results Program (SEER). Cancer stat facts. 2017. https://seer.cancer.gov/ (last accessed 7 September 2017). 2017 (https://seer.cancer.gov/statfacts/html/clyl.html

• 全文

6.  Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407-1427.

• 全文
• 摘要

7.  Leone G, Pagano L, Ben-Yehuda D, et al. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007;92:1389-1398.

• 全文
• 摘要

8.  Bizzozero D, Johnson K, Ciocco A. Radiation-related leukemia in Hiroshima and Nagasaki 1946-1964. I. Distribution, incidence and appearance time. N Engl J Med. 1966;274:1095-1101.

• 摘要

9.  Jacobs A. Benzene and leukemia. Br J Haematol. 1989;72:119-122.

• 摘要

10.  Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325:1682-1687.

• 摘要

11.  Pedersen-Bjergaard J, Christiansen DH, Andersen MK, et al. Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. Leukemia. 2002;16:2177-2184.

• 全文
• 摘要

12.  Pedersen-Bjeregaard J, Andersen MT, Andersen MK. Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2007:392-397.

• 全文
• 摘要

13.  Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100:2717-2723.

• 全文
• 摘要

14.  Falini B, Mecucci C, Tiacci C, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254-266.

• 全文
• 摘要

15.  Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752-1759.

• 全文
• 摘要

16.  Youn BS, Mantel C, Broxmeyer HE. Chemokines, chemokine receptors and hematopoiesis. Immunol Rev. 2000;177:150-174.

• 摘要

17.  Anderlini P, Luna M, Kantarjian HM, et al. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplatic syndromes. Leukemia. 1996;10:600-608.

• 摘要

18.  Seymour JF, Pierce SA, Kantarjian H, et al. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia. 1994;8:823-826.

• 摘要

19.  Howlader N, Noone AM, Krapcho M, et al, eds. Table 13.13: Myeloid leukemia: SEER Incidence rates, age-adjusted and age-specific Rates, by race and sex. In: SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute; 2014. Based on November 2013 SEER data submission, posted to the SEER web site, April 2014.

• 全文

20.  Maciejewski JP, Risitano A, Sloand EM, et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002;99:3129-3135.

• 全文
• 摘要

21.  Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999;340:1649-1660.

• 摘要

22.  Berk PD, Wasserman LR, Fruchtman SM, et al. Treatment of polycythemia vera: a summary of trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia vera and the myeloproliferative disorders. Philadelphia, PA: WB Saunders; 1995:166-194.

23.  Silverstein MN, Brown AL Jr, Linman JW. Idiopathic myeloid metaplasia. Its evolution into acute leukemia. Arch Intern Med. 1973;132:709-712.

• 摘要

24.  Rosenthal S, Canellos GP, DeVita VT Jr, et al. Characteristics of blast crisis in chronic granulocytic leukemia. Blood. 1977;49:705-714.

• 摘要

25.  Alter BP. Fanconi's anemia and malignancies. Am J Hematol. 1996;53:99-110.

• 摘要

26.  Bloom G, Warner S, Gerald P, Diamond JK. Chromosomal abnormalities in constitutional aplastic anemia. N Engl J Med. 1966;274:8-14.

• 摘要

27.  D'Andrea AD, Dahl N, Guinan EC, et al. Marrow failure. Hematology Am Soc Hematol Educ Program. 2002:58-72.

• 全文
• 摘要

28.  Gilman PA, Jackson DP, Guild HG. Congenital agranulocytosis, prolonged survival and terminal acute leukemia. Blood. 1970;36:576-585.

• 摘要

29.  Rosen RB, Kang SJ. Congenital agranulocytosis terminating in acute myelomonocytic leukemia. J Pediatr. 1979;94:406-408.

• 摘要

30.  Sieff CA, Nisbet-Brown E, Nathan DG. Congenital bone marrow failure syndromes. Br J Haematol. 2000;111:30-42.

• 摘要

31.  Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969;71:747-752.

• 摘要

32.  Smith ML, Cavenagh JD, Lister TA, et al. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004;351:2403-2407.

• 全文
• 摘要

33.  Bader J, Miller R. Neurofibromatosis and childhood leukemia. J Pediatr. 1978;92:925-929.

• 摘要

34.  Forestier E, Israeli S, Beverloo B, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008;11:1575-1583.

• 摘要

35.  Shimizu Y, Schull WJ, Kato H. Cancer risk among atomic bomb survivors. The RERF Life Span Study. Radiation Effects Research Foundation. JAMA. 1990;264:601-604.

• 摘要

36.  Rinsky RA, Smith AB, Hornung R, et al. Benzene and leukemia. An epidemiologic risk assessment. N Engl J Med. 1987;316:1044-1050.

• 摘要

37.  Kok PW, Ong CN. Blood and urinary benzene determined by headspace gas chromatography with photoionization detection: application in biological monitoring or low-level nonoccupational exposure. Int Arch Occup Environ Health. 1994;66:195-201.

• 摘要

38.  Hayes RB, Yin SN, Doemeci M, et al. Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine-National Cancer Institute Benzene Study Group. J Natl Cancer Inst. 1997;89:1065-1071.

• 全文
• 摘要

39.  Lan Q, Zhang L, Li G, et al. Hematotoxicity in workers exposed to low levels of benzene. Science. 2004;306:1774-1776.

• 全文
• 摘要

40.  Mele A, Szklo M, Visani G, et al. Hair dye use and other risk factors for leukemia and pre-leukemia: a case control study. Italian Leukemia Study Group. Am J Epidemiol. 1994;139:609-619.

• 摘要

41.  Brownson RC, Novotny TE, Perry MC. Cigarette smoking and adult leukemia. A meta-analysis. Arch Intern Med. 1993;153:469-475.

• 摘要

42.  Williams RR, Horm JW. Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: interview study from the Third National Cancer Survey. J Natl Cancer Inst. 1977;58:525-547.

• 摘要

43.  Blair A, Zahm SH, Pearce NE, et al. Clues to cancer etiology from studies of farmers. Scand J Work Environ Health. 1992;18:209-215.

• 摘要

44.  Metayer C, Johnson ES, Rice JC. Nested case-control study of tumors of the hemopoietic and lymphatic systems among workers in the meat industry. Am J Epidemiol. 1998;147:727-738.

• 全文
• 摘要

45.  Howlader N, Noone AM, Krapcho M, et al, eds. Table 13.8: Acute myeloid leukemia: age-adjusted SEER incidence rates by year, race and sex. In: SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute; 2014. Based on November 2013 SEER data submission, posted to the SEER web site, April 2014.

• 全文

46.  Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909-1918.

• 全文
• 摘要

47.  Pastore F, Dufour A, Benthaus T, et al. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2014;32:1586-1594.

• 摘要

48.  Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-474.

• 全文
• 摘要

49.  Mrózek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012;30:4515-4523.

• 全文
• 摘要

50.  de Greef GE, van Putten WL, Boogaerts M, et al. Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol. 2005;128:184-191.

• 摘要

51.  Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-4649.

• 摘要

52.  Marsh JC, Ball SE, Cavanagh J, et al; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147:43-70.

• 全文
• 摘要

53.  Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant. 2006;37:249-261.

• 全文
• 摘要

54.  National Cancer Comprehensive Network. NCCN guidelines: acute myeloid leukemia. Version 3. 2017. http://www.nccn.org (last accessed 21 June 2017).

• 全文

55.  Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249-1259.

• 全文
• 摘要

56.  Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31:3360-3368.

• 摘要

57.  Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010;28:586-595.

• 全文
• 摘要

58.  Lee JH, Joo YD, Kim H, et al; Cooperative Study Group A for Hematology. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood. 2011;118:3832-3841.

• 摘要

59.  Löwenberg B, Pabst T, Vellenga E, et al . Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364:1027-1036.

• 全文
• 摘要

60.  Willemze R, Suciu S, Meloni G, et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol. 2014;32:219-228.

• 摘要

61.  Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302-1311.

• 摘要

62.  Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009;27:5397-5403.

• 全文
• 摘要

63.  Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. Br J Haematol. 2011;155:366-376.

• 摘要

64.  Itzykson R, Gardin C, Pautas C, et al; Acute Leukemia French Association (ALFA). Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica. 2011;96:837-844.

• 全文
• 摘要

65.  Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235-1248.

• 全文
• 摘要

66.  Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23:1969-1978.

• 全文
• 摘要

67.  Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116:3751-3757.

• 全文
• 摘要

68.  Lo-Coco F, Avvisati G, Vignetti M, et al; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111-121.

• 全文
• 摘要

69.  Burnett AK, Russell NH, Hills RK, et al.; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16:1295-1305.

• 摘要

70.  Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35:605-612.

• 摘要

71.  Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocyticleukemia: very long-term results and role of maintenance. Blood. 2011;117:4716-4725.

• 全文
• 摘要

72.  Muchtar E, Vidal L, Ram R, et al. The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission. Cochrane Database Syst Rev. 2013;(3):CD009594.

• 全文
• 摘要

73.  Stanworth SJ, Estcourt LJ, Powter G, et al; TOPPS Investigators. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013;368:1771-1780.

• 全文
• 摘要

74.  Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998-3003.

• 全文
• 摘要

75.  ClinicalTrials.gov. A randomized study of gemtuzumab ozogamicin (GO) with daunorubicine and cytarabine in untreated acute myeloid leukemia (AML) aged of 50-70 years old. July 2013. https://clinicaltrials.gov/ (last accessed 26 September 2017).

• 全文

76.  Amadori S, Suciu S, Selleslag DJ, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. Clin Oncol. 2016;34:972-979.

• 全文
• 摘要

77.  Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017 June 23 [Epub ahead of print].

• 全文
• 摘要

78.  Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722-731.

• 摘要

79.  US Food and Drug Administration. FDA approves liposome-encapsulated combination of daunorubicin-cytarabine for adults with some types of poor prognosis AML. August 2017. https://www.fda.gov/ (last accessed 25 August 2017).

• 全文

80.  ClinicalTrials.gov. Phase III study of CPX-351 versus 7+3 in patients 60-75 years old with untreated high risk (secondary) acute myeloid leukemia (301). August 2017. https://clinicaltrials.gov/ (last accessed 25 August 2017).

• 全文

81.  Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106-1117.

• 全文
• 摘要

82.  Zirm E, Spies-Weisshart B, Heidel F, et al. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. Br J Haematol. 2012;157:483-492.

• 全文
• 摘要

83.  Levis MJ, Perl AE, Dombret H, et al. Final results of a phase 2 open-label monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. 2012 ASH Annual Meeting. Oral sessions: abstract 673. Blood (ASH Annual Meeting Abstracts). 2012;120:673.

84.  Tickenbrock L, Müller-Tidow C, Berdel WE,et al. Emerging Flt3 kinase inhibitors in the treatment of leukaemia. Expert Opin Emerg Drugs. 2006;11:153-165.

• 摘要

85.  NIHR Horizon Scanning Centre (NIHR HSC). Vosaroxin in combination with cytarabine for acute myeloid leukamaemia. June 2012. http://www.hsc.nihr.ac.uk/ (last accessed 21 June 2017).

• 全文

86.  Ravandi F, Ritchie EK, Sayar H, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015;16:1025-1036.

• 摘要

87.  Ganetsky A. The role of decitabine for the treatment of acute myeloid leukemia. Ann Pharmacother. 2012;46:1511-1517.

• 摘要

88.  Boumber Y, Kantarjian H, Jorgensen J, et al. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012;26:2428-2431.

• 摘要

89.  Saygin C, Carraway HE. Emerging therapies for acute myeloid leukemia. J Hematol Oncol. 2017;10:93.

• 全文
• 摘要

90.  ClinicalTrials.gov. Clinical Trial No. NCT02348489. SGI-110 in adults with untreated acute myeloid leukemia (AML), not considered candidates for intensive remission induction. https://clinicaltrials.gov (last accessed 21 June 2017).

• 全文

91.  Fenaux P, Mufti G, Santini V, et al. Azacitidine treatment prolongs overall survival in higher-risk MDS patients compared with conventional care regimens: results of the AZA-001 phase III study. Blood. 2007;110:250a.

92.  Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562-569.

• 全文
• 摘要

93.  National Institute for Health and Care Excellence (NICE). Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia. March 2011. http://www.nice.org.uk/ (last accessed 21 June 2017).

• 全文

94.  Ghanem H, Jabbour E, Faderl S, et al. Clofarabine in leukemia. Expert Rev Hematol. 2010;3:15-22.

• 摘要

95.  Milligan DW, Grimwade D, Cullis JO, et al; British Committee for Standards in Haematology. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol. 2006;135:450-474.

• 全文
• 摘要

96.  ClinicalTrials.gov. Clinical Trial No. NCT02298166. Study of crenolanib in combination with chemotherapy in patients with relapsed or refractory acute myeloid leukemia and activating FLT3 mutations. https://clinicaltrials.gov (last accessed 21 June 2017).

• 全文

97.  ClinicalTrials.gov. Clinical Trial No. NCT02152956. Safety study of MGD006 in relapsed/refractory acute myeloid leukemia (AML) or intermediate-2/high risk MDS. https://clinicaltrials.gov (last accessed 21 June 2017).

• 全文

98.  Howlader N, Noone AM, Krapcho M, et al, eds. Table 13.16: Acute myeloid leukemia - 5-year relative and period survival by race, sex, diagnosis year and age. In: SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute; 2014. Based on November 2013 SEER data submission, posted to the SEER web site, April 2014.

• 全文

99.  Burnett AK, Milligan D, Goldstone A, et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol. 2009;145:318-332.

• 摘要

100.  Kelaidi C, Chevret S, De Botton S, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol. 2009;27:2668-2676.

• 摘要

101.  Gurion R, Belnik-Plitman Y, Gafter-Gvili A, et al. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev. 2012;(6):CD008238.

• 全文
• 摘要

102.  Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010;28:2914-2924.

• 摘要